The sigma-1 receptor chaperone as an inter-organelle signaling modulator

Trends in Pharmacological Sciences

Volumn 31, Issue 12, 2010, Pages 557-566

  Su, Tsung Ping ^a   Hayashi, Teruo ^a   Maurice, Tangui ^b,c   Buch, Shilpa ^d   Ruoho, Arnold E ^e  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b University of Montpellier   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 1,3 BIS(2 METHYLPHENYL)GUANIDINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 4 PHENYL 1 (4 PHENYLBUTYL)PIPERIDINE; ANAVEX 2 73; ANTIOXIDANT; BD 1063; CHLORPHENIRAMINE; DEXTROMETHORPHAN; FENPROPIMORPH; FLUVOXAMINE; HALOPERIDOL; IMMUNOSUPPRESSIVE AGENT; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL) 2 PROPENYLAMINE; NEUROPROTECTIVE AGENT; PENTAZOCINE; PRASTERONE; PRE 085; PROGESTERONE; QUINIDINE; RIMCAZOLE; SIGMA 1 OPIATE RECEPTOR; SPHINGOSINE; UNCLASSIFIED DRUG; VERAPAMIL;

ALZHEIMER DISEASE; AMNESIA; CALCIUM HOMEOSTASIS; CELLULAR DISTRIBUTION; DEPRESSION; DRUG BINDING SITE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; LEARNING DISORDER; LIGAND BINDING; LIPID RAFT; LOW DRUG DOSE; MITOCHONDRION; MITOCHONDRION ASSOCIATED ENDOPLASMIC RETICULUM MEMBRANE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SHORT SURVEY;

ANIMALS; CALCIUM; DENDRITIC SPINES; DRUG DELIVERY SYSTEMS; ENDOPLASMIC RETICULUM; HUMANS; LIGANDS; MITOCHONDRIA; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; MOLECULAR STRUCTURE; PROTEIN TRANSPORT; RECEPTORS, SIGMA; SIGNAL TRANSDUCTION;

EID: 78449290844     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.08.007     Document Type: Short Survey

References (109)

1. Su T.-P., et al. Steroid binding at sigma receptors suggest a link between endocrine, nervous, and immune systems. Science 1988, 240:219-221.
2. Snyder S.H., Largent B.L. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J Neuropsychiatry Clin. Neurosci. 1989, 1:7-15.
3. Quirion R., et al. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13:85-87.
4. Hayashi T., Su T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007, 131:596-610.
5. Tsai S.-Y., et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive Rac.GTP pathway. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:22468-22473.
6. Meunier J., Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J. Pharmacol. Exp. Ther. 2010, 332:388-397.
7. Hayashi T., Fujimoto M. Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. Mol. Pharmacol. 2010, 77:517-528.
8. Hayashi T., Su T.P. Intracellular dynamics of sigma-1 receptors (sigma(1) binding sites) in NG108-15 cells. J. Pharmacol. Exp. Ther. 2003, 306:726-733.
9. Hayashi T., Su T.P. Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J. Pharmacol. Exp. Ther. 2003, 306:718-725.
10. Maurice T., Su T.-P. The pharmacology of sigma-1 receptors. Pharmacol. Ther. 2009, 124:195-206.
11. Fontanilla D., et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323:934-937.
12. Fishback J.A., et al. Sigma receptors: potential targets for a new class of antidepressant drugs. Pharmacol. Ther. 2010, 127:271-282.
13. Hanner M., et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8072-8077.
14. Kekuda R., et al. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 1996, 229:553-558.
15. Prasad P.D., et al. Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 sigma receptor gene. J. Neurochem. 1998, 70:443-451.
16. Seth P., et al. Cloning and functional characterization of a sigma receptor from rat brain. J. Neurochem. 1998, 70:922-931.
17. Mei J., Pasternak G.W. Molecular cloning and pharmacological characterization of the rat sigma1 receptor. Biochem. Pharmacol. 2001, 62:349-355.
18. Moebius F.F., et al. High affinity of sigma 1-binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8-C7 isomerase. Br. J. Pharmacol. 1997, 121:1-6.
19. Silve S., et al. Emopamil-binding protein, a mammalian protein that binds a series of structurally diverse neuroprotective agents, exhibits delta8-delta7 sterol isomerase activity in yeast. J. Biol. Chem. 1996, 271:22434-22440.
20. Aydar E., et al. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002, 34:399-410.
21. Ramachandran S., et al. Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli. Protein Expr. Purif. 2007, 51:283-292.
22. Chen Y., et al. Characterization of the cocaine binding site on the sigma-1 receptor. Biochemistry 2007, 46:3532-3542.
23. Pal A., et al. Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol. Pharmacol. 2007, 72:921-933.
24. Guo L.W., et al. Sulfhydryl-reactive, cleavable, and radioiodinatable benzophenone photoprobes for study of protein-protein interaction. Bioconjug. Chem. 2005, 16:685-693.
25. Pal A., et al. Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor. J. Biol. Chem. 2008, 283:19646-19656.
26. Fontanilla D., et al. Probing the steroid binding domain-like I (SBDLI) of the sigma-1 receptor binding site using N-substituted photoaffinity labels. Biochemistry 2008, 47:7205-7217.
27. Ganapathy M.E., et al. Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. J. Pharmacol. Exp. Ther. 1999, 289:251-260.
28. Seth P., et al. Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor. Biochim. Biophys. Acta 2001, 1540:59-67.
29. Yamamoto H., et al. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Lett. 1999, 445:19-22.
30. Tam S.W. (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, mu, kappa, delta and phencyclidine binding sites in guinea pig brain membranes. Eur. J. Pharmacol. 1985, 109:33-41.
31. Tam S.W., Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:5618-5621.
32. Weber E., et al. 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:8784-8788.
33. Tam S.W. Naloxone-inaccessible sigma receptor in rat central nervous system. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:6703-6707.
34. de Costa B.R., et al. Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands. J. Med. Chem. 1989, 32:1996-2002.
35. de Costa B.R., et al. Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett. 1989, 251:53-58.
36. Ablordeppey S.Y., et al. Is a nitrogen atom an important pharmacophoric element in sigma ligand binding?. Bioorg. Med. Chem. 2000, 8:2105-2111.
37. Glennon R.A., et al. Structural features important for sigma 1 receptor binding. J. Med. Chem. 1994, 37:1214-1219.
38. McCann D.J., et al. Sigma-1 and sigma-2 sites in rat brain: comparison of regional, ontogenetic, and subcellular patterns. Synapse 1994, 17:182-189.
39. Moebius F.F., et al. Yeast sterol C8-C7 isomerase: identification and characterization of a high-affinity binding site for enzyme inhibitors. Biochemistry 1996, 35:16871-16878.
40. Gray N.M., et al. H1 antihistamines interact with central sigma receptors. Life Sci. 1990, 47:175-180.
41. Nguyen E.C., et al. Involvement of sigma receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 2005, 49:638-645.
42. Sharkey J., et al. Cocaine binding at sigma receptors. Eur. J. Pharmacol. 1988, 149:171-174.
43. Narita N., et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol. 1996, 307:117-119.
44. Cagnotto A., et al. [3H](+)pentazocine binding to rat brain sigma-1 receptors. Eur. J. Pharmacol. 1994, 266:131-138.
45. Ramachandran S., et al. The sigma-1 receptor interacts with N-alkylamines and endogenous sphingolipids. Eur. J. Pharmacol. 2009, 609:19-26.
46. Su T.-P., et al. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. J. Pharmacol. Exp. Ther. 1991, 259:543-550.
47. Matsumoto R.R., et al. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur. J. Pharmacol. 1995, 280:301-310.
48. Ferris R.M., et al. Evidence that the potential antipsychotic agent rimcazole (BW234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci. 1986, 38:2329-2337.
49. Okuyama S., et al. NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci. 1993, 53:PL285-290.
50. Glennon R.A. Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the " deconstruction-reconstruction-elaboration" approach. Mini Rev. Med. Chem. 2005, 5:927-940.
51. Wang Y., et al. Interactions of metaphit with phencyclidine and sigma agonist actions in rat cerebellum: determination of specificity and selectivity. J. Pharmacol. Exp. Ther. 1987, 241:321-327.
52. Maurice T., et al. Behavioral evidence for a modulating role of sigma ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia. Brain Res. 1994, 647:44-56.
53. 25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998, 83:413-428.
54. Okuyama S., et al. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine- induced delayed cognitive dysfunction in rats. Neurosci. Lett. 1995, 189:60-62.
55. Hayashi T., Su T.P. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:491-496.
56. Hayashi T., Su T.P. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14949-14954.
57. Palmer C.P., et al. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res. 2007, 67:11166-11175.
58. Ramachandran S., et al. The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur. J. Pharmacol. 2009, 609:19-26.
59. Rusinol A.E., et al. A unique mitochondria-associated membrane fraction from rat liver has a high capacity for lipid synthesis and contains pre-Golgi secretory proteins including nascent lipoproteins. J. Biol. Chem. 1994, 269:27494-27502.
60. Mavlyutov T.A., Ruoho A.E. Ligand-dependent localization and intracellular stability of sigma-1 receptors in CHO-K1 cells. J. Mol. Signal. 2007, 2:8.
61. Hayashi T., Su T.-P. Subcellular localization and intracellular dynamics of σ1 receptors. Sigma Receptors: Chemistry, Cell Biology and Clinical Implications 2007, 151-164. Springer. R.R. Matsumoto (Ed.).
62. Meunier J., et al. Compensatory effect by sigma-1 receptor stimulation during alcohol withdrawal in mice performing an object recognition task. Behav. Brain Res. 2006, 166:166-176.
63. Soriani O., et al. A-Current down-modulated by sigma receptor in frog pituitary melanotrope cells through a G protein-dependent pathway. J. Pharmacol. Exp. Ther. 1999, 289:321-328.
64. Soriani O., et al. The sigma-ligand (+)-pentazocine depresses M current and enhances calcium conductances in frog melanotrophs. Am. J. Physiol. 1999, 277:E73-80.
65. Hayashi T., Su T. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr. Neuropharmacol. 2005, 3:267-280.
66. Wilke R.A., et al. Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells. J. Biol. Chem. 1999, 274:18387-18392.
67. Kennedy C., Henderson G. Inhibition of potassium currents by the sigma receptor ligand (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine in sympathetic neurons of the mouse isolated hypogastric ganglion. Neuroscience 1990, 35:725-733.
68. Monassier L., et al. Sigma(2)-receptor ligand-mediated inhibition of inwardly rectifying K(+) channels in the heart. J. Pharmacol. Exp. Ther. 2007, 322:341-350.
69. Zhang H., Cuevas J. Sigma receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J. Pharmacol. Exp. Ther. 2005, 313:1387-1396.
70. Zhang H., Cuevas J. Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. J. Neurophysiol. 2002, 87:2867-2879.
71. Hayashi T., et al. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J. Pharmacol. Exp. Ther. 2000, 293:788-798.
72. Monnet F.P., et al. N-methyl-d-aspartate-induced neuronal activation is selectively modulated by sigma receptors. Eur. J. Pharmacol. 1990, 179:441-445.
73. Monnet F.P., et al. Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 2003, 307:705-712.
74. Kume T., et al. Antagonism of NMDA receptors by sigma receptor ligands attenuates chemical ischemia-induced neuronal death in vitro. Eur. J. Pharmacol. 2002, 455:91-100.
75. Hayashi T., et al. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-d-aspartate in primary culture of rat frontal cortical neurons. J. Pharmacol. Exp. Ther. 1995, 275:207-214.
76. Martina M., et al. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J. Physiol. 2007, 578:143-157.
77. Langa F., et al. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur. J. Neurosci. 2003, 18:2188-2196.
78. Johannessen M.A., et al. Voltage-gated sodium channel modulation by sigma receptors in cardiac myocytes and heterologous systems. Am. J. Physiol. Cell Physiol. 2009, 296:C1049-C1057.
79. Carnally S.M., et al. Demonstration of a direct interaction between sigma-1 receptors and acid-sensing ion channels. Biophys. J. 2010, 98:1182-1191.
80. Su T.P., et al. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci. Signal. 2009, 2:pe12.
81. Kim F.J., et al. Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol. Pharmacol. 2009, 77:695-703.
82. Mavlyutov T.A., et al. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 2010, 167:247-255.
83. Hayashi T., et al. Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J. Pharmacol. Exp. Ther. 2010, 332:1054-1063.
84. Yagasaki Y., et al. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J. Biol. Chem. 2006, 281:12941-12949.
85. Yao H., et al. Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood 2010, 115:4951-4962.
86. Hiranita T., et al. Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine. J. Pharmacol. Exp. Ther. 2010, 332:515-524.
87. Villard V., et al. Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative anavex1-41 against amyloid β25-35-induced toxicity in mice. Neuropsychopharmacology 2009, 34:1552-1566.
88. Villard, V. et al. (2010) Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J. Psychopharmacol. ; Sept 7. doi:10.1177/0269881110379286.
89. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
90. Uchida N., et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am. J. Geriatr. Psychiatry 2005, 13:1062-1066.
91. Marrazzo A., et al. Neuroprotective effects of sigma-1 receptor agonists against β-amyloid-induced toxicity. Neuroreport 2005, 16:1223-1226.
92. 1 receptor. Br. J. Pharmacol. 2006, 149:998-1012.
93. Li, L. et al. (2010) DHEA prevents Aβ25-35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling. Neuropharmacology 59, 323-333.
94. 1-receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion. Stroke 2000, 31:976-982.
95. Goyagi T., et al. Neuroprotective effect of sigma1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. Stroke 2001, 32:1613-1620.
96. Ajmo C.T., et al. Sigma receptor activation reduces infarct size at 24hours after permanent middle cerebral artery occlusion in rats. Curr. Neurovasc. Res. 2006, 3:89-98.
97. Katnik C., et al. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J. Pharmacol. Exp. Ther. 2006, 319:1355-1365.
98. Shen Y.C., et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J. Neurochem. 2008, 104:558-572.
99. Anderson T.R., Andrew R.D. Spreading depression: imaging and blockade in the rat neocortical brain slice. J. Neurophysiol. 2002, 88:2713-2725.
100. Haiman G., et al. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect. J. Clin. Psychopharmacol. 2009, 29:444-452.
101. Gekker G., et al. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. Int. Immunopharmacol. 2006, 6:1029-1033.
102. Roth M.D., et al. Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. J. Leukoc. Biol. 2005, 78:1198-1203.
103. Berthois Y., et al. SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo. Br. J. Cancer 2003, 88:438-446.
104. Jbilo O., et al. Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J. Biol. Chem. 1997, 272:27107-27115.
105. Casellas P., et al. Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses. J. Neuroimmunol 1994, 52:193-203.
106. Vilner B.J., et al. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J. Neurosci. 1995, 15:117-134.
107. Wang B., et al. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res. Treat. 2004, 87:205-214.
108. Spruce B.A., et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004, 64:4875-4886.
109. Cardenas C., et al. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell 2010, 142:270-283.